Leflunomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury

Expert Opinion on Drug Safety

Volumn 10, Issue 4, 2011, Pages 603-611

  Inokuma, Shigeko ^a  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

interstitial lung disease; interstitial pneumonia pneumonitis; leflunomide; lymphopenia; rheumatoid arthritis

Indexed keywords

AUROTHIOMALATE; COLESTYRAMINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE;

AUTOPSY; DEATH; DIFFERENTIAL DIAGNOSIS; DRUG HALF LIFE; DYSPNEA; FEVER; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; LOADING DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAINTENANCE DRUG DOSE; POSTMARKETING SURVEILLANCE; RESPIRATORY DISTRESS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

ANIMALS; ANTIRHEUMATIC AGENTS; HUMANS; ISOXAZOLES; JAPAN; LUNG DISEASES, INTERSTITIAL; LUNG INJURY;

EID: 79958860140     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.560835     Document Type: Review

References (25)

1. Arava tablet 10 mg/20 mg/100 mg. Pharmaceuticals and Medical Devices Agency. Tokyo, 2010. Available from: http://www.info.pmda.go.jp/go/pack/ 3999020F1029-1-11/ [Last accessed August 2010]
2. Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004;43:1201-4 (Pubitemid 40074162)
3. Takeishi M, Akiyama Y, Akiba H, et al. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005;32:1160-3 (Pubitemid 40828105)
4. Ochi S, Harigai M, Mizoguchi F, et al. Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage. Mod Rheumatol 2006;16:316-20 (Pubitemid 44575260)
5. Hirabayashi Y, Shimizu H, Kobayashi N, Kudo K. Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis. Intern Med 2006;45:689-91 (Pubitemid 43905484)
6. Otsuka T, Koyama T, Ohtani R, et al. Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. Mod Rheumatol 2008;18:96-9
7. Sawada T, Inokuma S, Sato T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1069-72
8. Vallbracht I, Popper HH, Rieber JF, et al. Lethal pneumonitis under leflunomide therapy. Rheumatology 2005;44:1580-1
9. Hashimoto K, Nakanishi H, Yamasaki A, et al. Pulmonary findings without the influence of therapy in a patient with rheumatoid arthritis: an autopsy case. J Med Invest 2007;54:340-4 (Pubitemid 350143748)
10. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004;44:585-96 (Pubitemid 38845105)
11. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:143-7 (Pubitemid 38219666)
12. Sato T, Inokuma S, Sagawa A, et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48:1265-8
13. Inokuma S, Sato T, Sagawa A, et al. Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. Mod Rheumatol 2008;18:442-6
14. Chikura B, Lane S, Dawson JK. Clinical expression of leflunomide-induced pneumonitis. Rheumatology 2009;48:1065-8
15. Savage RL, Highton J, Boyd IW, Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006;36:162-9
16. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006;54:1435-9
17. Ju J, Kim Sl, Lee J, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007;56:2094-6 (Pubitemid 47110410)
18. Balakrishnan C, Dasgupta B. Pulmonary adverse events with leflunomide-myth or reality? Rheumatology (Oxford) 2007;46:372 (Pubitemid 46189811)
19. Saravanan V, Kelly C. Drug-related pulmonary problems in patients with rheumatoid arthritis. Rheumatology 2006;45:787-9 (Pubitemid 43985362)
20. Wong SP, Chu CM, Kan CH, et al. Successful treatment of leflunomide-induced acute pneumonitis with cholestyramine wash-out therapy. J Clin Rheumatol 2009;15(8):389-92
21. Miwa Y, Isozaki T, Wakabayashi K, et al. Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis. Mod Rheumatol 2008;18:208-11
22. Tacrolimus hydrate capsule 0.5 mg/1 mg. Pharmaceuticals and Medical Devices Safety Information No. 231. Available from: http://www. mhlw.go.jp/houdou/2006/12/h1221-4. html [Last accessed December 2006]
23. Inokuma S, Kono H, Kohno Y, et al. Methotrexate-induced lung injury in patients with rheumatoid arthritis occurs with peripheral blood lymphocyte count decrease. Ann Rheum Dis 2006;65:1113-14 (Pubitemid 44133279)
24. The Study Committee for Leflunomide-induced Lung Injury, the Japan College of Rheumatology. Lung injury under the use of leflunomide. 22nd Annual Meeting of Kanto Area of the Japan College of Rheumatology; Tokyo 2007
25. Nakagawa M, Nishimura T, Teramukai S, et al. Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02. BMC Res Notes 2009;2:157